

Unveiling the oncogenic significance of thymidylate synthase in human cancers

Yibo Geng, PhD<sup>1</sup>, Luyang Xie, MD<sup>2</sup>, Yang Wang, PhD<sup>1</sup>, Yan Wang\*, MD<sup>1</sup>  
1 Department of Neurosurgery, Beijing Chaoyang Hospital, Capital Medical University  
2 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University

Yibo Geng and Luyang Xie contributed equally to this work.

Corresponding author

Yan Wang  
Department of Neurosurgery, Beijing Chaoyang Hospital, Capital Medical University, No.8, South Road of Workers Stadium, Chaoyang District, Beijing, 100020, China.  
Email: 13801110536@163.com

## Abstract

**Background:** Thymidylate synthase (TYMS) constitutes a pivotal and potent target in the context of chemoresistance. However, the oncogenic role of TYMS has received insufficient attention.

**Methods:** Leveraging data from the Cancer Genome Atlas and various public databases, we conducted an extensive investigation into the oncogenic role of TYMS across 33 cancer types.

**Results:** TYMS exhibited pronounced expression across a spectrum of cancers and demonstrated associations with clinical outcomes in diverse cancer patient cohorts. Furthermore, genetic alterations were identified as potential influencers of overall survival in specific tumor types. Notably, the expression of thymidylate synthase correlated with tumor-infiltrating CD4<sup>+</sup> cells in select cancers. Additionally, the functional mechanism of TYMS encompassed nucleotidase activity, chromosome segregation, and DNA replication progress.

**Conclusions:** This study furnishes a comprehensive understanding of the oncogenic role played by TYMS in human tumors.

**Keywords:** thymidylate synthase, tumor, TCGA, prognosis, tumor-infiltrating immune cell

## Abbreviations

ACC	Adrenocortical carcinoma
BLCA	Bladder Urothelial Carcinoma
BRCA	Breast invasive carcinoma
	Cervical squamous cell carcinoma and endocervical
CESC	adenocarcinoma
CHOL	Cholangiocarcinoma
COAD	Colon adenocarcinoma
DFS	Disease free survival
DLBC	Diffuse Large B-cell Lymphoma
dTMP	deoxythymidine monophosphate
ESCA	Esophageal carcinoma
GBM	Glioblastoma
GEPIA2	Gene Expression Profiling Interactive Analysis, version 2
GTEX	Genotype-Tissue Expression
HNSC	Head and Neck squamous cell carcinoma
HPA	The Human Protein Atlas
IHC	Immunohistochemistry
KICH	Kidney Chromophobe
KIRC	Kidney renal clear cell carcinoma
KIRP	Kidney renal papillary cell carcinoma
LAML	Acute Myeloid Leukemia
LGG	Low grade glioma
LIHC	Liver hepatocellular carcinoma
LUAD	Lung adenocarcinoma
LUSC	Lung squamous cell carcinoma
MESO	Mesothelioma
MHC	major histocompatibility complex
NCBI	National Center for Biotechnology Information
NK	Natural killer
NSCLC	non-small cell lung carcinoma
OS	Overall survival
OV	Ovarian serous cystadenocarcinoma

PAAD	Pancreatic adenocarcinoma
PCPG	Pheochromocytoma and Paraganglioma
PRAD	Prostate adenocarcinoma
READ	Prostate adenocarcinoma
SARC	Sarcoma
SKCM	Skin Cutaneous Melanoma
STAD	Stomach adenocarcinoma
TCGA	The cancer genome atlas
TGCT	Testicular Germ Cell Tumors
THCA	Testicular Germ Cell Tumors
THYM	Thymoma
TIMER2	tumor immune estimation resource, version 2
TPM	Transcripts per million
TYMS	thymidylate synthase
UCEC	Uterine Corpus Endometrial Carcinoma
UCS	Uterine Carcinosarcoma
UVM	Uveal Melanoma

## Introduction

The exploration of novel oncogenes is crucial for achieving a comprehensive understanding of the mechanisms underlying malignant tumors and identifying potential therapeutic targets[1]. Utilizing resources such as The Cancer Genome Atlas and various other publicly available analysis websites, which house valuable genomics and proteomics information[2], facilitates interactive analyses specifically focused on unraveling the oncogenic role of thymidylate synthase (TYMS).

TYMS, a human nucleotide enzyme, plays a pivotal role in endogenous thymidylate synthesis, enabling de novo production of thymidylate. While TYMS has been extensively studied in contexts such as hepatitis, rheumatic diseases, and neural development[3-5], recent investigations have increasingly highlighted its significance in chemoresistance and tumorigenesis[6, 7]. This paper synthesizes findings from laboratory-based experiments involving cell or animal models, elucidating the intricate relationship between TYMS and various malignancies (Figure 1) [8-24].

In our study, we employed data from The Cancer Genome Atlas and several public databases to analyze oncologic features, encompassing gene expression, survival rates, genetic alterations, phosphorylation sites, immune cell infiltration, and related gene functions. This comprehensive approach aims to provide a detailed understanding of the oncogenic mechanisms governed by TYMS.

## Materials and Methods

### Gene location and protein structure analysis

The genomic location of the TYMS gene was determined based on the UCSC genome browser (GRCh38/hg38) [25]. Utilizing the "HomoloGene" function of the NCBI, conserved functional domain analysis of the TYMS protein across different species was conducted. The three-dimensional structure of TYMS was obtained using the cBioPortal web tool[26].

### Gene expression analysis

#### TIMER2

Differences in TYMS expression were assessed using the "Gene\_DE" module of the Tumor Immune Estimation Resource, version 2 (TIMER2) [27]. In cases lacking contrast tissues or a sufficient contrast group, the Gene Expression Profiling Interactive Analysis, version 2 (GEPIA2) web server from Genotype-Tissue Expression (GTEx) was employed[28]. Violin plots depicting TYMS expression across various pathological stages were generated using the "Pathological Stage Plot" module in GEPIA2, utilizing log<sub>2</sub> [TPM (Transcripts per million)

+1] transformed expression results with a log-scale test.

HPA

The Human Protein Atlas (HPA) database provided TYMS expression data in different cells, tissues, and plasma[29]. Plasma sample data were estimated through mass spectrometry-based proteomics, defining "low specificity" as "Normalized expression  $\geq 1$  in at least one tissue/cell type, but not elevated in any tissue/cell type." Immunohistochemistry (IHC) images of TYMS in five pairs of normal and tumor tissues (BRCA, COAD, LIHC, and LUAD) were downloaded from HPA and analyzed.

### **Survival analysis**

Utilizing the Kaplan-Meier "Survival Map" module in GEPIA2, overall survival (OS) and disease-free survival (DFS) maps for TYMS were obtained. The expression threshold for categorizing high/low expression groups was set at 50%. Kaplan-Meier survival analysis in GEPIA2 generated survival plots using the log-rank test.

### **Genetic alteration analysis**

Genetic alteration features, alteration frequency, mutation type, and mutated site information for TYMS were collected from the cBioPortal web. Overall survival data for tumors with or without TYMS genetic alterations were collected, and Kaplan-Meier analysis with log-rank P-values was performed.

### **Phosphorylation feature**

The predicted phosphorylation features of TYMS at sites S6, T53, S114, S124, Y146, S151, Y153, S154, and T167 were obtained from the open-access PhosphoNET database by searching the protein name "TYMS."

### **Immune infiltration cell analysis**

The association between TYMS expression and immune infiltrates, specifically CD4<sup>+</sup> T-cells, CD8<sup>+</sup> T-cells, cancer-associated fibroblasts, and NK cells, was explored using the TIMER2 web tool. Purity-adjusted Spearman's rank correlation test provided P-values and partial correlation (cor) values.

### **TYMS-related gene enrichment**

The STRING website was employed to identify TYMS-binding proteins[30], with a low confidence score set at 0.7. Interaction types were based on the maximum number of interactors ( $\leq 50$ ), full STRING network, and confidence.

### **Data availability**

The datasets analyzed in this study are available in the online dataset. Requests for further access to the dataset can be directed to [yibo.geng@ccmu.edu.cn](mailto:yibo.geng@ccmu.edu.cn).

## **Results**

### **Gene location and protein structure**

In our study, we investigated the oncogenic function of TYMS (NM\_001071 or NP\_001062.1, Supplementary Figure 1A). The protein structure demonstrated conservation across various species (Supplementary Figure 1B, C).

### **Gene expression analysis**

The expression levels of TYMS in various normal tissues and blood cells were assessed. The thymus exhibited the highest TYMS expression, followed by bone marrow and tonsil. TYMS displayed a tissue-enhanced (immune tissues) expression pattern, detected in all tissues except skeletal muscle and tongue (Figure 2A). Blood cell analysis showed low specificity, with markedly elevated TYMS expression in regulatory T cells (Figure 2B).

TYMS expression in multiple tumors, including BLCA, BRCA, CESC, CHOL, COAD, ESCA, GBM, HNSC, KIRC, KIRP, LIHC, LUAD, LUSC, PCPG, STAD, THCA, and UCEC, was higher than in corresponding normal tissues (Figure 3A,  $P < 0.01$ ). Further analysis using the GTEx dataset revealed significant differences in expression levels between tumor and normal tissue in additional cancers (Figure 3B,  $P < 0.05$ ). However, TYMS expression in KICH, PRAD, TGCT, or THCA was similar to normal tissue (Supplementary Figure 2,  $P > 0.05$ ).

Positive correlations were found between TYMS expression and pathological stages in ACC, KICH, LIHC, and TGCT. Conversely, COAD, LUSC, and OV showed negative correlations (Figure 4). No correlation was observed in other cancers (Supplementary Figure 3).

### **Immunohistochemistry difference**

Comparison of TYMS staining between normal and tumor tissues via IHC corroborated TYMS expression patterns in the HPA dataset. Medium or strong TYMS staining was observed in BRCA, COAD, LIHC, and LUAD, while low or negative staining was evident in normal comparable tissues (Figure 5).

### **Survival analysis**

High TYMS expression correlated with poor overall survival in ACC ( $P < 0.001$ , HR=3.8), KICH ( $P < 0.05$ , HR=9.2), LGG ( $P < 0.001$ , HR=2.1), LIHC ( $P < 0.001$ , HR=1.8), LUAD ( $P < 0.001$ , HR=1.7), MESO ( $P < 0.001$ , HR=3.3) and SARC ( $P < 0.01$ , HR=1.8) (Figure 6A). Similarly, it was associated with poor DFS in ACC ( $P < 0.001$ , HR=4.9), KICH ( $P < 0.05$ , HR=4.9), LGG ( $P < 0.01$ , HR=1.5), LIHC ( $P < 0.001$ , HR=1.8), PRAD ( $P < 0.001$ , HR=2.0) and SARC ( $P < 0.05$ , HR=1.5) (Figure 6B). While TYMS showed varied associations with outcomes across different cancers, certain cancers, including ACC, KICH, LGG, LIHC and SARC exhibited consistent tendencies in both OS and DFS (Figure 6).

### **Genetic alteration**

The genetic alteration of TYMS has been observed in distinct tumors. The highest alteration frequency of TYMS (>4%) found in patients with bladder cancer was amplification (Figure 7A). The types, sites, and number of TYMS genetic alterations are depicted in Figure 7B. Overall survival in the TYMS alteration group was significantly shorter than in the wild type for both BLCA (P<0.01) and LUAD (P<0.05).

### **Phosphorylation analysis**

Phosphorylation site analysis of TYMS in mammals was achieved using the PhosphoNET database (Supplementary Figure 4). Unfortunately, limited studies explored phosphorylation differences between tumor and normal tissues, preventing a comprehensive summary of the implications of TYMS phosphorylation in tumors.

### **Immune infiltration analysis**

Tumor-infiltrating immune cells can enhance the development, progression, or metastasis of cancers[31]. A significant negative relationship was found between CD4+ T cells and TYMS expression in BLCA, DLBC, and MESO (Figure 8A). Additionally, a significant relationship between TYMS expression and cancer-associated fibroblasts was observed for BRCA, HNSC, KICH, STAD, TGCT, and THYM. Among them, BRCA, HNSC, STAD, and THYM exhibited a negative correlation (Figure 8B). However, similar trends were not observed in CD8+ and NK cell types (Supplementary Figure 5).

### **Enrichment analysis of TYMS-related genes**

Fifty TYMS-binding proteins were identified through the STRING tool (Figure 9A). The top 100 TYMS-correlated targeting genes were summarized, with the top five being NDC80, EZH2, NUSAP1, WDR76, and MCM6. Notably, five genes overlapped in the two datasets (Figure 9B). The expression of these interacted genes (CDC45, MAD2L1, MCM5, NUSAP1, and PCAN) positively correlated with TYMS expression across almost all types of cancers (Figure 9C, D).

Finally, GO analysis for these genes indicated their predominant location in the chromosomal region and execution of nucleotidase activity (Figure 10B, C). Furthermore, these genes were enriched in DNA replication, chromosome segregation, and nuclear division.

### **Discussion**

TYMS, a folate-dependent essential enzyme, plays a pivotal role in generating intracellular de novo dTMP, critical for DNA synthesis and repair[32]. Its involvement extends beyond tumorigenesis, encompassing functions in coronary artery



disease[33], virus replication and congenital disorder[34, 35]. This diversity underscores the significance of TYMS in various pathological contexts. The expanding literature linking TYMS to tumors prompted our comprehensive analysis to elucidate its oncogenic role in diverse cancer types.

The conservation of TYMS protein structure across species suggests shared physiological mechanisms. Notably, TYMS expression was detectable in most normal tissues and consistently elevated in tumor tissues compared to their normal counterparts. This widespread expression underscores the potential influence of TYMS in various cellular processes.

High TYMS expression consistently correlated with shorter overall survival and advanced tumor stage across multiple cancers. This association could be attributed to TYMS's dual role: directly promoting tumor cell proliferation and inducing chemoresistance. Mechanistically, TYMS has been implicated in promoting cell proliferation and maintaining the de-differentiated state in breast cancer through distinct pathways[12, 36, 37]. Additionally, TYMS contributed to multiple drug resistance, impacting responses to 5-FU in COAD[6], temozolomide in glioma[38], pemetrexed in breast cancer/ MESO[39, 40], and platinum in NSCLC[41].

The interaction between TYMS and tumor-infiltrating immune cells highlights its role in the tumor microenvironment. A statistically significant difference was found between TYMS and CD4+ T-cells in BLCA, DLBC, MESO and TGCT (Figure 8A), which was similar with the previous studies. Dersh et al indicated that TYMS inhibitor increased MHC-1 presentation in DLBC, which revealed the role of TYMS in manipulating immunosurveillance in cancers[42]. Wang et al demonstrated that TYMS suppression impaired helper T cells (Th1 & Th17) differentiation and immune response[43]. Recently, a phase I clinical trial of thymidylate synthase poly-epitope-peptide vaccine against metastatic colorectal cancer induced immune-biological effects and showed antitumor activity[44]. Also, a positive correlation between TYMS and cancer-associated fibroblast in KICH and TGCT which need further investigations. Above all, these results provided evidence that TYMS have a complicated correlation with immune system and deserved further studies in tumor immunology and microenvironment.

Enrichment analysis combining TYMS-binding components and expression-related genes revealed the central involvement of "nucleotidase activity" and "DNA replication" in tumor cell proliferation. These processes are pivotal in the progression of

tumors, emphasizing the need for further experimental validation to elucidate the specific oncogenic role of TYMS. Future studies should delve into the molecular mechanisms underlying TYMS-mediated tumor progression and its potential as a therapeutic target.

### **Conclusion**

Based on a comprehensive analysis across various tumors, we found a factual association between TYMS expression and clinical outcome, protein phosphorylation and immune cell infiltration, as well as relating genes and functions, which could help to better understand the oncogenic role of TYMS.

### **Author contribution**

YG performed the most data analysis and assisted with the writing of the manuscript; LX performed the rest data analysis; YG, Yang W and Yan W designed the study and assisted with the writing of the manuscript; YG and Yan W performed the literature search and collected the data; Yan W supervised the study; All authors have read and approved the manuscript.

### **Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### **Acknowledgements**

This work was supported by the Beijing Municipal Natural Science Foundation (No. 7244344), Beijing Chao-yang Hospital Golden Seed foundation (No. CYJZ202201) and the inner-hospital foundation of Beijing Chao-yang Hospital. Besides, we would like to thank Xulei Huo for his technical supports.

### **Reference**

- [1] Kontomanolis EN, Koutras A, Syllaios A, Schizas D, Mastoraki A, Garpis N, Diakosavvas M, Angelou K, Tsatsaris G, Pagkalos A, Ntounis T and Fasoulakis Z. Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. *Anticancer Res* 2020; 40: 6009-6015.
- [2] Blum A, Wang P and Zenklusen JC. SnapShot: TCGA-Analyzed Tumors. *Cell* 2018; 173: 530.
- [3] Wang X, Guan Z, Dong Y, Zhu Z, Wang J and Niu B. Inhibition of thymidylate synthase affects neural tube development in mice. *Reprod Toxicol* 2018; 76: 17-25.

- [4] Zhao Z, He S, Yu X, Lai X, Tang S, Mariya ME, Wang M, Yan H, Huang X, Zeng S and Zha D. Analysis and Experimental Validation of Rheumatoid Arthritis Innate Immunity Gene CYFIP2 and Pan-Cancer. *Front Immunol* 2022; 13: 954848.
- [5] Meng Q, Li X and Xiong X. Identification of Hub Genes Associated With Non-alcoholic Steatohepatitis Using Integrated Bioinformatics Analysis. *Front Genet* 2022; 13: 872518.
- [6] Varghese V, Magnani L, Harada-Shoji N, Mauri F, Szydlo RM, Yao S, Lam EW and Kenny LM. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. *Sci Rep* 2019; 9: 1505.
- [7] Zhang S, Yan L, Cui C, Wang Z, Wu J, Zhao M, Dong B, Guan X, Tian X and Hao C. Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence. *Oncol Rep* 2020; 44: 565-576.
- [8] Vijayakurup V, Maeng K, Lee HS, Meyer B, Burkett S, Nawab A, Dougherty MW, Jobin C, Mahmud I, Garrett TJ, Feely M, Lee KB, Kaye FJ, Guijarro MV and Zajack M. Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival. *JCI Insight* 2022; 7:
- [9] Kumar A, Singh AK, Singh H, Thareja S and Kumar P. Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer. *Med Oncol* 2022; 40: 3.
- [10] Costantino L, Ferrari S, Santucci M, Salo-Ahen OMH, Carosati E, Franchini S, Lauriola A, Pozzi C, Trande M, Gozzi G, Saxena P, Cannazza G, Losi L, Cardinale D,

Venturelli A, Quotadamo A, Linciano P, Tagliazucchi L, Moschella MG, Guerrini R, Pacifico S, Luciani R, Genovese F, Henrich S, Alboni S, Santarem N, da Silva Cordeiro A, Giovannetti E, Peters GJ, Pinton P, Rimessi A, Cruciani G, Stroud RM, Wade RC, Mangani S, Marverti G, D'Arca D, Ponterini G and Costi MP. Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth. *Elife* 2022; 11:

- [11] Banerjee S, Michalarea V, Ang JE, Ingles Garces A, Biondo A, Funingana IG, Little M, Ruddle R, Raynaud F, Riisnaes R, Gurel B, Chua S, Tunariu N, Porter JC, Prout T, Parmar M, Zachariou A, Turner A, Jenkins B, McIntosh S, Ainscow E, Minchom A, Lopez J, de Bono J, Jones R, Hall E, Cook N, Basu B and Banerji U. A Phase I Trial of CT900, a Novel alpha-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer. *Clin Cancer Res* 2022; 28: 4634-4641.
- [12] Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins S, Saatci O, Annaratone L, Hm Schellens J, Kim B, Asangani IA, Rasheed SAK, Marchio C, Sahin O and Ceppi P. Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. *Cell Death Differ* 2019; 26: 2223-2236.
- [13] Li B, Xu WW, Guan XY, Qin YR, Law S, Lee NP, Chan KT, Tam PY, Li YY, Chan KW, Yuen HF, Tsao SW, He QY and Cheung AL. Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance. *Clin Cancer Res* 2016; 22: 1243-

1255.

- [14] Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K and Wada H. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. *Clin Cancer Res* 2007; 13: 6938-6946.
- [15] Longley DB, Allen WL, McDermott U, Wilson TR, Latif T, Boyer J, Lynch M and Johnston PG. The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. *Clin Cancer Res* 2004; 10: 3562-3571.
- [16] Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ and Zajac-Kaye M. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. *Cancer Cell* 2004; 5: 341-351.
- [17] Matuszyk J. MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy. *Mol Med* 2022; 28: 89.
- [18] Ciszewski WM, Chmielewska-Kassassir M, Wozniak LA and Sobierajska K. Thymidylate Synthase Overexpression Drives the Invasive Phenotype in Colon Cancer Cells. *Biomedicines* 2022; 10:
- [19] Nagaraju GP, Alese OB, Landry J, Diaz R and El-Rayes BF. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. *Oncotarget* 2014; 5: 9980-9991.
- [20] Mannava S, Moparthy KC, Wheeler LJ, Leonova KI, Wawrzyniak JA, Bianchi-Smiraglia A, Berman AE, Flanagan S, Shewach DS, Zeitouni NC, Gudkov AV, Mathews CK and Nikiforov MA. Ribonucleotide reductase and thymidylate synthase

or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion. *Aging (Albany NY)* 2012; 4: 917-922.

- [21] Fazzone W, Wilson PM, Labonte MJ, Lenz HJ and Ladner RD. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. *Int J Cancer* 2009; 125: 463-473.
- [22] Sakatani A, Sonohara F and Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. *Carcinogenesis* 2019; 40: 422-431.
- [23] Li XY, Wang DP, Lu GQ, Liu KL, Zhang TJ, Li S, Mohamed OK, Xue WH, Qian XH and Meng FH. Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLC. *J Adv Res* 2020; 26: 95-110.
- [24] Ko JC, Tsai MS, Chiu YF, Weng SH, Kuo YH and Lin YW. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells. *J Pharmacol Exp Ther* 2011; 338: 184-194.
- [25] Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM and Haussler D. The human genome browser at UCSC. *Genome Res* 2002; 12: 996-1006.
- [26] Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C and Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci Signal* 2013; 6: p11.

- [27] Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B and Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. *Nucleic Acids Res* 2020; 48: W509-W514.
- [28] Tang Z, Kang B, Li C, Chen T and Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. *Nucleic Acids Res* 2019; 47: W556-W560.
- [29] Ponten F, Jirstrom K and Uhlen M. The Human Protein Atlas--a tool for pathology. *J Pathol* 2008; 216: 387-393.
- [30] Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ and Mering CV. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019; 47: D607-D613.
- [31] Zhang Y and Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. *Cell Mol Immunol* 2020; 17: 807-821.
- [32] Wilson PM, Danenberg PV, Johnston PG, Lenz HJ and Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. *Nat Rev Clin Oncol* 2014; 11: 282-298.
- [33] Kim JO, Ryu CS, Lee JY, Ko EJ, Ha YH, Sung JH, Hwang TS, Kim IJ and Kim NK. Association of Thymidylate Synthase (TS) Gene Polymorphisms with Incidence and Prognosis of Coronary Artery Disease. *Int J Mol Sci* 2023; 24:
- [34] Desrosiers V, Barat C, Breton Y, Ouellet M and Tremblay MJ. Thymidylate synthase

- is essential for efficient HIV-1 replication in macrophages. *Virology* 2021; 561: 47-57.
- [35] Zhu H, Yang W, Shaw N, Perloff S, Carmichael SL, Finnell RH, Shaw GM and Lammer EJ. Thymidylate synthase polymorphisms and risk of conotruncal heart defects. *Am J Med Genet A* 2012; 158A: 2194-2203.
- [36] Derenzini M, Montanaro L, Trere D, Chilla A, Tazzari PL, Dall'Olio F and Ofner D. Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines. *Mol Pathol* 2002; 55: 310-314.
- [37] Zhang F, Ye J, Guo W, Zhang F, Wang L and Han A. TYMS-TM4SF4 axis promotes the progression of colorectal cancer by EMT and upregulating stem cell marker. *Am J Cancer Res* 2022; 12: 1009-1026.
- [38] Zhao M, Tan B, Dai X, Shao Y, He Q, Yang B, Wang J and Weng Q. DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide. *Eur J Pharmacol* 2019; 863: 172665.
- [39] Sato Y, Tomita M, Soga T, Ochiai A and Makinoshima H. Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma. *Front Pharmacol* 2021; 12: 718675.
- [40] Shan F, Liu YL, Wang Q and Shi YL. Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer. *Oncol Lett* 2018; 16: 3274-3280.
- [41] Agullo-Ortuno MT, Garcia-Ruiz I, Diaz-Garcia CV, Enguita AB, Pardo-Marques V, Prieto-Garcia E, Ponce S, Iglesias L, Zugazagoitia J, Lopez-Martin JA, Paz-Ares L and Nunez JA. Blood mRNA expression of REV3L and TYMS as potential predictive



biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients. *Cancer Chemother Pharmacol* 2020; 85: 525-535.

- [42] Dersh D, Phelan JD, Gumina ME, Wang B, Arbuckle JH, Holly J, Kishton RJ, Markowitz TE, Seedhom MO, Fridlyand N, Wright GW, Huang DW, Ceribelli M, Thomas CJ, Lack JB, Restifo NP, Kristie TM, Staudt LM and Yewdell JW. Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity* 2021; 54: 116-131 e110.
- [43] Wang J, Peng L, Zhang R, Zheng Z, Chen C, Cheung KL, Cui M, Bian G, Xu F, Chiang D, Hu Y, Chen Y, Lu G, Yang J, Zhang H, Yang J, Zhu H, Chen SH, Liu K, Zhou MM, Sikora AG, Li L, Jiang B and Xiong H. 5-Fluorouracil targets thymidylate synthase in the selective suppression of TH17 cell differentiation. *Oncotarget* 2016; 7: 19312-19326.
- [44] Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG and Tagliaferri P. Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. *Oncotarget* 2018; 9: 20539-20554.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6






Figure 7











Figure 10



### Figure legends

**Figure 1.** Schematic depicting the relationship between TYMS and various tumors.

**Figure 2.** TYMS expression in normal organ. (A) Expression level of TYMS in normal human tissues. Different color indicated different human system. (B) TYMS expression in normal blood immune cells.

**Figure 3.** TYMS expression difference across various tumors. (A) TYMS expression between various tumors and comparable normal tissues through TCGA dataset. (B) TYMS expression through TCGA and GTEx dataset. \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$

**Figure 4.** TYMS expression difference across pathological stages in seven tumor types.

**Figure 5.** IHC difference between normal and tumor tissues in BRCA (A), COAD (B), LIHC (C) and PRAD (D). ( $P < 0.05$ )

**Figure 6.** Correlation between TYMS expression and the survival outcome of tumors. OS (A) and DFS (B) was presented in heat bar. The significantly similar trend between OS was DFS was ACC, KICH, LGG, LIHC and SARC, which was displayed in survival map. ( $P < 0.05$ )

**Figure 7.** Mutation feature of TYMS. The alteration frequency with mutation type (A) and mutation site (B) is displayed. (C) There are significant overall survival differences between TYMS alteration and wild-type in BLCA and LUAD ( $P < 0.05$ ).

**Figure 8.** Correlation between TYMS and CD4+ immune cells (A) and cancer associated fibroblast (B).

**Figure 9.** TYMS-related gene analysis. (A) Top 50 TYMS-binding proteins and their relationship. (B) The overlap part between the FASN-binding and correlated genes. (C) Expression analysis between TYMS and the five interacting genes in (B). (D) (C) displayed through heatmap across cancers.

**Figure 10.** GO analysis of TYMS-related genes. Biological process (A), cellular component (B) and molecular function (C) was displayed.

**Supplementary Figure 1.** Structural characteristics of TYMS. (A) Gene location of TYMS. (B) Conserved domain of TYMS. (C) Three-dimension structure of TYMS.

**Supplementary Figure 2.** TYMS expression showed no difference between KICH, PRAD, TGCT and THCA and their comparable normal tissues.

**Supplementary Figure 3.** TYMS expression across pathological stages showed no difference in these tumors.

**Supplementary Figure 4.** Phosphoprotein site of TYMS showed in the axis

**Supplementary Figure 5.** Correlation between TYMS and CD8+ immune cells (A) and NK cells (B).

**Supplementary File 1.** The reference list related to TYMS phosphoprotein site in mammals.

**Supplementary Table 1.** Top 100 TYMS-correlated genes